Vanda Pharmaceuticals' HETLIOZ sNDA for Jet Lag Disorder Rejected by FDA After Re-review

summarizeSummary

Vanda Pharmaceuticals announced that the FDA has again rejected its supplemental New Drug Application (sNDA) for HETLIOZ for the treatment of jet lag disorder, concluding it cannot be approved in its current form.

check_boxKey Events

• FDA Rejects HETLIOZ sNDA for Jet Lag

  Vanda Pharmaceuticals received a letter from the FDA stating that its supplemental New Drug Application (sNDA) for HETLIOZ (tasimelteon) for the treatment of jet lag disorder cannot be approved in its current form following an expedited re-review.

• Disagreement on Efficacy Evidence

  The FDA acknowledged positive efficacy from Vanda's clinical trials but concluded the data did not provide substantial evidence of effectiveness, primarily arguing that controlled phase advance protocols are not sufficiently analogous to actual jet travel conditions.

• Company Plans to Challenge Decision

  Vanda Pharmaceuticals respectfully disagrees with the FDA's interpretation, maintaining that its submitted dataset meets the statutory standard for effectiveness, and is committed to pursuing all appropriate avenues for approval.

• Follows Prior Court Ruling

  This decision comes after the D.C. Circuit in August 2025 set aside a prior FDA refusal for the same sNDA, leading to the collaborative framework agreement for the expedited re-review.

auto_awesomeAnalysis

The FDA's second rejection of HETLIOZ for jet lag disorder, even after a court had previously set aside an earlier refusal, represents a significant regulatory setback for Vanda Pharmaceuticals. The core disagreement over the validity of simulated jet lag protocols versus actual travel conditions indicates a fundamental hurdle in the approval pathway. While Vanda plans to pursue all appropriate avenues, this decision creates substantial uncertainty for the commercialization of HETLIOZ in this new indication and could lead to prolonged legal or regulatory battles, impacting the company's near-term growth prospects.